| (Values in U.S. Thousands) | Dec, 2024 | Dec, 2023 | Dec, 2022 | Dec, 2021 | Dec, 2020 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | -15,020 | -15,420 | -14,320 | -7,710 | -14,130 |
| Net Income Growth | +2.59% | -7.68% | -85.73% | +45.44% | +70.32% |
Indaptus Therapeutics Inc (INDP)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
0.7203 -0.0349 (-4.62%) 03/21/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 0.7306 +0.0103 (+1.43%) 18:47 ET
for Fri, Mar 21st, 2025
Indaptus Therapeutics approach is based on the hypothesis which efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals. Indaptus Therapeutics, formerly known as Intec Parent Inc., is based in NEW YORK.
Fiscal Year End Date: 12/31